| Treating cancers with a cyclin-dependent kinase inhibitor |
2022-6-08 |
2023-1-05 |
|
| Anti-cancer nuclear hormone receptor-targeting compounds |
2022-5-02 |
2022-12-01 |
|
| Heterocyclic compounds as kinase inhibitors |
2022-5-02 |
2022-11-10 |
|
| Heterocyclic compounds as kinase inhibitors |
2022-5-02 |
2022-11-10 |
|
| Heterocyclic compounds as kinase inhibitors |
2022-5-02 |
2022-11-10 |
|
| Heterocyclic compounds as kinase inhibitors |
2022-5-02 |
2022-11-10 |
|
| Heterocyclic compounds and uses thereof |
2022-4-08 |
2023-4-06 |
|
| Anti-cancer nuclear hormone receptor-targeting compounds |
2022-3-22 |
2022-9-29 |
|
| Heterocyclic compounds as adenosine antagonists |
2022-3-02 |
2022-9-22 |
|
| 1,8-naphthyridinone compounds and uses thereof |
2022-2-18 |
2022-6-02 |
|
| Heterocyclic compounds as kinase inhibitors |
2022-2-10 |
2022-4-01 |
|
| Crystalline forms of a cyclin-dependent kinase inhibitor |
2022-2-02 |
2022-8-11 |
|
| Heterocyclic compounds as bet inhibitors |
2021-12-27 |
2022-2-01 |
|
| Heterocyclic compounds as kinase inhibitors |
2021-12-26 |
2022-2-01 |
|
| 1,8-naphthyridinone compounds and uses thereof |
2021-12-13 |
2022-7-14 |
|
| Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet … |
2021-12-02 |
2022-7-07 |
|
| Anticancer compounds targeting nuclear hormone receptors |
2021-11-12 |
2022-9-23 |
|
| Heterocyclic compounds and uses thereof |
2021-10-12 |
2022-4-21 |
|
| Heterocyclic compounds and uses thereof |
2021-10-06 |
2021-12-01 |
|
| Heterocyclic compounds as kinase inhibitors |
2021-10-01 |
2023-3-02 |
|
| Compounds and uses thereof |
2021-7-11 |
2021-8-31 |
|
| Heterocyclic compounds as adenosine antagonists |
2021-7-11 |
2021-8-31 |
|
| Diarylhydantoin compounds and methods of use thereof |
2021-5-24 |
2021-7-29 |
|
| Pyrrole and pyrazole compounds and methods of use thereof |
2021-5-23 |
2021-7-29 |
|
| Heterocyclic compounds as bet inhibitors |
2021-4-28 |
2023-3-08 |
|
| Heterocyclic compounds as adenosine antagonists |
2021-2-12 |
2021-9-23 |
|
| Heterocyclic compounds as adenosine antagonists |
2021-1-15 |
2021-7-22 |
|
| Heterocyclic compounds as adenosine antagonists |
2021-1-15 |
2021-7-22 |
|
| ANTI-CANCER COMPOUNDS TARGETING THE NUCLEAR HORMONE RECEPTOR |
2020-11-13 |
2022-3-02 |
|
| Anti-cancer nuclear hormone receptor-targeting compounds |
2020-11-06 |
2021-6-21 |
|
| Heterocyclic compounds as kinase inhibitors |
2020-8-13 |
2022-6-22 |
|
| Anti-cancer nuclear hormone receptor-targeting compounds |
2020-5-14 |
2021-3-01 |
|
| Heterocyclic compounds and uses thereof |
2020-4-08 |
2023-1-04 |
|
| Heterocyclic compounds and uses thereof |
2020-4-08 |
2020-10-15 |
|
| Heterocyclic compounds and uses thereof |
2020-4-08 |
2020-10-15 |
|
| Heterocyclic compounds and uses thereof |
2020-4-08 |
2022-5-26 |
|
| HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
2020-1-17 |
2021-9-21 |
|
| Anti-cancer nuclear hormone receptortargeting compounds. |
2019-5-14 |
2021-12-13 |
|
| Heterocyclic compounds and uses thereof |
2018-10-09 |
2019-4-11 |
|
| Compostos heterocíclicos como antagonistas de adenosina |
2020-1-17 |
2021-9-21 |
|